ClinicalTrials.gg
RecruitingNCT06111274Updated Apr 11, 2024

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

A Phase 2 interventional study of Pimicotinib (ABSK021) in Advanced Pancreatic Cancer, sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 359 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
194th of 508
82 · median 58
Started
2023
with 63 others
Phase 2
155 of 630
89 open now
Primary completion
2025-12
later than 95 of 358 live
Registered
342nd of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 194th largest by planned enrollment of the 508 interventional ones that give a count, is one of 64 that started in 2023, is one of 155 in phase 2, reaches primary completion later than 95 of the 358 other live ones, and was the 342nd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are:

  • Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer.
  • Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer.

Participants will be asked to complete the study procedures:

  • Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab about 24 weeks in study Part A or Part B.
  • Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2.
  • Complete the study procedures specified in the protocol, which is guided by researchers.
Read the detailed description

This is a phase II, open-label study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical benefit of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer.

03

Conditions studied

  • Advanced Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female aged 18-75 years old. The subjects must have to the study, and signed the written informed consent voluntarily.
  • Diagnosis as non resectable local advanced or pancreatic cancer by histology or cytology.
  • as defined by 1.1.
  • Without systemic treatment for pancreatic cancer.
  • physical strength score 0-2
  • Estimated survival time >=3 months.
  • The adequate bone marrow fuction and coagulation function

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to any components of the drug product.
  • Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R).
  • With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation.
  • With a history of other within 5 years.
  • During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment.
  • With conditions that significantly affected the absorption of oral drug.
  • Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds.
  • During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic treatment or any other form of treatment.
  • Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 () within 14 days prior to randomization.
  • Previous peripheral neuropathy > grade 1 (, version 5.0).
  • Diagnosed with immune deficiency or interstitial lung disease.
  • The patients were vaccinated within 4 weeks before the first treatment.
  • Participated in any drug clinical trial within 4 weeks before the first treatment.
  • Active central nervous system (CNS) .
  • Impaired cardiac function or cardiac disease.
  • Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study.
  • Known active infections from certain viruses, bacteria or parasites.
  • Patients with /uncontrolled ascites or pleural effusion.
  • Pregnant or lactating women.
  • Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    ABSK021 with chemotherapy

    There are 2 cohorts in both part A and Part B. In cohort 1, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel) , 3 weeks as one cycle, about 8 cycles in total.

    Drug: Pimicotinib (ABSK021)

  • Experimental
    ABSK021 in combination with chemotherapy plus the Toripalimab

    There are 2 cohorts in both part A and Part B. In cohort 2, the participant will receive the treatment of ABSK021 in combination with chemotherapy (the Gemcitabine and nab-Pacilitaxel), with Toripalimab, 3 weeks as one cycle, about 8 cycles in total.

    Drug: Pimicotinib (ABSK021)

Interventions

  • The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.

    Also known as: Gemcitabine, nab-Pacilitaxel, Toripalimab

06

What researchers measure

Primary outcomes

  1. Safety Event Occurance

    The Number of Participants With Adverse Event (AE), a Serious Adverse Event (SAE) and Dose Limiting Toxicities (DLT) Event.

    Time frame: From the day signed informed consent form to day 90 after the end of cycle 8 (each cycle is 21 days)

  2. Objective Response Rate (ORR)

    The Percentage of Participants with confirmed Complete Response and Partial Response, in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)

    Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

Secondary outcomes

  1. Duration of Response

    Duration of response (DOR) is defined as the time from the date of the first documentation of confirmed response (Complete Response or Partial Response) to the first objective documentation of progressive disease (PD) per RECIST v1.1 per Investigator assessment, or to death due to any cause in the absence of documented PD.

    Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

  2. Progression Free Survival

    Progression-free survival (PFS) was defined as as the time from the first dose to the first objectively documented disease progression per RECIST v1.1 per Investigator assessment, or death due to any cause in the absence of documented progressive disease (PD). PFS was analyzed using Kaplan-Meier methods.

    Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

  3. Overall Survival

    Overall survival (OS) was defined as the time from first dose of study drug to death due to any cause. OS was calculated using the Kaplan-Meier method.

    Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

  4. The exposure of ABSK021

    The Area Under the Concentration Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Normalized by Dose.

    Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

  5. The Maximum Concentration of ABSK021

    Maximum Observed Concentration (Cmax)

    Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

  6. The Minimum Concentration of ABSK021

    Minimum Observed Concentration (Cmin)

    Time frame: From the cycle 1 day 1 to the end of cycle 8 (each cycle is 21 days)

07

Study locations

5 of 5 sites recruiting
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai, China
    Recruiting
    • Liwei Wang · Contact
    • Liwei Wang · Principal investigator
  • West China Hospital of Sichuan University
    Chengdu, China
    Recruiting
    • Dan Cao · Contact
    • Dan Cao · Principal investigator
  • Harbin Medical University Cancer Hospital
    Ha'erbin, China
    Recruiting
    • Zhiwei Li · Contact
    • Zhiwei Li · Principal investigator
  • Shanghai East Hospital Tongji University
    Shanghai, China
    Recruiting
    • Ming Quan · Contact
    • Ming Quan · Principal investigator
  • Union Hospital Tongji Medical College Huazhong University of science and technolog
    Wuhan, China
    Recruiting
    • Tao Zhang · Contact
    • Tao Zhang · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 26 months is below that.

Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Nov 1, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 29, 2026
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111274
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Oct 17, 2023
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 29, 2026 (estimated)
Last update
Apr 11, 2024

Study contacts

YUAN LU
Contact
clinical@abbisko.cn
+86-21-68910052

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimicotinib

Start the discussion